Government of Colorado Report issue

Government Phase 3

Organization Overview

First Clinical Trial
2018
NCT03474029
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Denver Public Health (USA)

Active Ingredients

Drugs in Phase 3 Trials (3)

isoniazid (nydrazid) (1 trial)

rifampin (1 trial)

rifapentine (priftin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Latent Tuberculosis (Phase 3)

Tuberculosis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 3